Acronym BIOaptAA Title Bioengineering to Advance Personalized Therapies for Aplastic Anemia Summary

Idiopathic aplastic anemia (AA) is a rare disease characterized by a bone marrow (BM) hypocellularity, in which hematopoietic cells are replaced by fat cells, resulting in severe reductions in the numbers of hematopoietic stem/progenitor cells (HSPC). Despite the first line treatment option for severe AA would be allogeneic hematopoietic cell transplant (HCT), this procedure is not always feasible or well-succeeded, due to several constraints (e.g. unavailability of a suitable donor; risk of toxicity and engraftment failure, especially in older patients; rejection, which is estimated to occur in 5% to 15% of patients with severe AA undergoing BM transplantation).

Project webpage Start year 1/6/2025 End year 31/05/2028 ID ID: 16890 iBB Role Coordinator iBB Budget 173,577.60 € Research Group SCERG PI Cláudia Lobato da Silva Project Partners INESC-MN Status Ongoing Funding FCT - Fundação para a Ciência e Tecnologia / P2030